Consort Medical (CSRT) Stock Rating Upgraded by Royal Bank of Canada

Royal Bank of Canada upgraded shares of Consort Medical (LON:CSRT) to an outperform rating in a research note released on Tuesday. The brokerage currently has GBX 1,320 ($17.25) price target on the stock, down from their previous price target of GBX 1,430 ($18.69).

Separately, Shore Capital reaffirmed a hold rating on shares of Consort Medical in a report on Monday, September 10th.

LON CSRT opened at GBX 730 ($9.54) on Tuesday. Consort Medical has a 1 year low of GBX 976.09 ($12.75) and a 1 year high of GBX 1,230 ($16.07).

The company also recently disclosed a dividend, which will be paid on Friday, February 15th. Shareholders of record on Thursday, January 17th will be given a dividend of GBX 7.60 ($0.10) per share. This represents a yield of 0.99%. The ex-dividend date of this dividend is Thursday, January 17th.

Consort Medical Company Profile

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.

Recommended Story: Discount Rate

Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply